Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik unloaded 43,699 shares of the stock on the open market in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $38.80, for a total transaction of $1,695,521.20. The sale was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

A number of research firms have recently commented on KPTI. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One analyst has rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $52.67.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 4.73% on Thursday, hitting $36.06. The stock had a trading volume of 49,480 shares. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock has a 50-day moving average of $36.29 and a 200-day moving average of $34.62. The company’s market cap is $1.178 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings data on Thursday, August 7th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.52. Analysts expect that Karyopharm Therapeutics will post $-2.19 EPS for the current fiscal year.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.